Windward Bio

Windward Bio is a clinical-stage drug development company dedicated to improving outcomes for patients with advanced immune diseases, initially focusing on severe respiratory conditions. The company is led by a team of experienced biopharmaceutical executives with deep expertise in discovery, development, and commercialization. It is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into Phase 2 development and creating novel long-acting bispecific programs for immune-mediated diseases. WIN378 is a novel recombinant fully human monoclonal antibody that effectively binds to the TSLP ligand, a well-validated cytokine playing a critical role in the onset and progression of various immune diseases, including asthma and COPD. In both diseases, inhibition of the TSLP ligand has demonstrated benefits across multiple inflammatory phenotypes. Designed for extended half-life and effector silencing, WIN378 is administered subcutaneously.